OHSU

Tibor Kovacsovics, M.D.

Head Shot of Tibor Kovacsovics
Email: 
click here
Office: 
503 494-5058

Background

Dr. Kovacsovics research focuses on clinical trials with new agents for treatment of acute leukemias.


Selected Publications

"Functional integration of acute myeloid leukemia into the vascular niche," Leukemia - 2014

"Induction Bortezomib in AL Amyloidosis Followed By High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study," Clinical Lymphoma, Myeloma and Leukemia - 2014

"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML," Blood (Vol: 123, Issue: 21, Page 3239-3246) - 2014

"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening," Cancer Research (Vol: 73, Issue: 1, Page 285-296) - 2013

"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I trial," Journal of Clinical Oncology (Vol: 30, Issue: 20, Page 2492-2499) - 2012

 

OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


Contact

  Email Tibor Kovacsovics

503 494-5058

Memberships & Associations

American Society of Hematology hematology/oncology)